Changes in the USP heparin monograph and implications for clinicians

Pharmacotherapy

Volumn 30, Issue 5, 2010, Pages 428-431

  Smythe, Maureen A ^a,b   Nutescu, Edith A ^c   Wittkowsky, Ann K ^d  

^a BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Drug safety; Pharmacy practice

Indexed keywords

CHONDROITIN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTAMINATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; DRUG POTENCY; EDITORIAL; HEALTH CARE PERSONNEL; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PRACTICE GUIDELINE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; DRUG MONITORING; HEPARIN; HUMANS; PHARMACOPOEIAS AS TOPIC; PROTHROMBIN; REFERENCE STANDARDS; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 77951742223     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.5.428     Document Type: Editorial

References (20)

1. Szajek A, Jameison F. USP heparin monograph revisions - stage 2 and beyond. Available from http://www.usp.org/pdf/EN/meetings/workshops/ heparin2009Szajek.pdf. Accessed January 29, 2010.
2. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008;359(25):2674-2684
3. U.S. Pharmacopeia. USP heparin information. Available from www.usp.org/hottopics/heparin. Accessed January 29, 2010.
4. U.S. Food and Drug Administration. FDA public health alert: change in heparin USP monograph. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm. Accessed January 29, 2010.
5. U.S. Food and Drug Administration. FDA alert: New USP standards for heparin products will result in decreased potency. Adjustments may be needed to achieve desired anticoagulant effect in some patients. New heparin to ship starting October 8. Available from http:// www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm184674.htm. Accessed January 29, 2010.
6. American College of Chest Physicians. FDA announces new standards for heparin. Available from www.chestnet.org/accp/article/fda-announces-new- standards-heparin. Accessed January 29, 2010.
7. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based practice guidelines (8th edition). Chest 2008;133:141S-59.
8. Nutescu E, Singh-Khalsa M, and the Heparin Consensus Group. Treatment of venous thromboembolism: challenging the unfractionated heparin standard. Pharmacotherapy 2004;24(8 pt 2):127S-31.
9. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based practice guidelines (8th edition). Chest 2008;133:454S-545.
10. American College of Cardiology, American Heart Association. 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). J Am Coll Cardiol 2007;50:1-157.
11. Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring. Part 2: unfractionated heparin and low molecular-weight heparin. Ann Pharmacother 2005;39:1275-1285
12. Smythe MA, Koerber JM, Westley SJ, et al. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol 2001;115:148-155
13. Smythe MA, Koerber JM, Nowak SN, et al. Correlation between the activated clotting times and activated partial thromboplastin times. Ann Pharmacother 2002;36(1):7-11.
14. Francis JL, Groce JB III, and the Heparin Consensus Group. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy 2004;24(8 pt 2):108S-19.
15. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96:547-552 (Pubitemid 44782532)
16. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy, laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1988;122:782-798
17. Smythe MA, Koerber JM, Westley SJ, Balasubramaniam M, Mattson JC. Different heparin lots, does it matter? Arch Pathol Lab Med 2001;125:1458-1462
18. Kovacs MJ, Keeney M, Mackinnon K, et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21:55-60.
19. Baker BA, Adelman MS, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997;147:2475-2479
20. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935-942